EpiPen Pricing Got Mylan In Hot Water; Now Sanofi Is Taking Firm To Court

Sanofi claims Mylan blocked its competing Auvi-Q product from the market by offering rebates to payers on the condition they would only reimburse for EpiPen; Sanofi seeks treble damages for lost sales.